PURPOSE: To obtain the titled preparation comprising human interferon as an active ingredient.

CONSTITUTION: A solution containing human interferon (h-IFN: h-IFN of natural type, produced by chemical synthesis or by gene recombination technology: h-IFN-α, h-IFN-β, etc.) is brought into contact with an insoluble blue carrier, h-IFN is adsorbed on the blue carrier, the h-IFN is recovered as a solution by the use of an eluate, then the h-IFN substance is brought into contact with a chelate group bonded carrier having chelated zinc and the h-IFN is recovered as a solution by the use of an eluate to give concentrated and purified h-IFN. The h-IFN may be optionally mixed with a stabilizer (e.g. human serum albumin, polyol, etc.). Injection capsule agent, nasotracheal agent, suppository, oral drug, ointment, etc., may be cited as the dosage form. A dose is 300,000W6,000,000 units and administered one timeWseven times/week.